Medical Article

Paraphrasing is a manner how we are inquired to be more creative to change every single word without varying the meaning the primary text using own words. It takes our capable of looking up some unfamiliar words, applying for synonym words. However, notice how paraphrase looks like, such as how long the length of the paragraph, how many words and sentence structures are changed, but it does not change the tenses of the article. Overall, do not do plagiarism of your paraphrased text to original text. See how to follow steps avoid being plagiarism above. 

Summary is a step how we support our important main thought of the topic about, and summarizing is used to let readers know how the ending is of the story. Make sure that the length of the paragraph is shorter, and also make sure that use your own words and own sentence structure without changing the primary of the original text. The summary will look amazing to understand if some of us use transition signals. 

Source: Medical Writing Samples – The Medical Reporter: Writing On Health (wordpress.com)

Medical Article Writing

For the past 50 years, the National Cancer Institute’s Clinical Trials Cooperative Group Program has played a key role in developing new and improved cancer therapies and preventive strategies. NCI-sponsored trials have studied distinct cancer subpopulations and those with rare cancers, elucidated the role of therapeutic and chemoprevention agents such as tamoxifen for breast cancer, and evaluated quality-of-life issues for patients with cancer. But a new report from the Institute of Medicine (IOM) of the National Academies concludes that the Clinical Trials Cooperative Group Program is in a “state of crisis.” The IOM report recommends 12 sweeping changes in the ways that their clinical trials are reviewed, prioritized, and funded-changes that are likely to affect players as diverse as NCI and the FDA, clinical research investigators, cancer patients, and even health-care insurers and the pharmaceutical industry. More than 25,000 cancer patients, 3,100 institutions, and 14,000 investigators from cancer centers and community oncology practices participate in Cooperative Group clinical trials each year-and they would all likely be affected by the IOM’s recommended changes.

“Many people involved in the Cooperative Group clinical trials, including NCI and those doing research in the academic community and practice community, shared the same frustrations. The Cooperative Group trials system had become inefficient and slow, and we were not adequately funding and incentivizing people to participate-including patients and physicians,” said John Mendelsohn, MD, Chair of the IOM committee and President of The University of Texas M. D. Anderson Cancer Centre. “There was too much recycling of efforts, and too much gathering of opinions and counter opinions to design the trials. Everything needed to be streamlined.”

*Paraphrasing:

As the result, there are some recent cancer treatments and avoidance plans which were being constantly expanding by the National Cancer Institute’s Clinical Trials Cooperative Group Program as long during in half-century ago.  NCI-sponsored trials had been tested by such experiments to find divergent cancer classes, and previously mentioned of infrequent diseases of cancers; The institute had clarified and analyzed for recovery-of-life that chemotherapy, and kinds of cures would aid patients in cancers, especially for those are breast cancers given tamoxifen. At this point, the condition notifies opposite that the Clinical Trials Cooperative Group Program, from the Institute of Medicine of the National Academies announcement, is in a “state of crisis.” At that time, it might be any extensive developments available for NCI and the FDA, clinical research investigators, cancer patients, and even health-care insurers and the pharmacy industry, based on the reports of the IOM will be provided to any needed most. As long as the changes provided by the IOM, they had collaborated with Cooperative Group Clinical Trials in each-annual-year that survey showed above 25,000 cancer patients, 3,100 institutions, and 14,000 investigators from cancer center departments and section of oncology operation had eventually had those changes.

A lot of protest of medical people, and staffs, whom those connected to Cooperative Group Clinical Trials, was received. John Mendelsohn, MD, Chair of the IOM committee and President of The University of Texas M. D. Anderson Cancer Centre said that Cooperative Group Clinical Trials had been very steady, weak, and can’t pay for patients and doctors to connect and many things which was unexpected to be improved as soon as possible, and there are a few recommendations and critics underestimated to grow the Cooperative Group Clinical Trials better.

*Summary:  

In conclusion, executing productively and consistently, and making strategies right have to be applied for any actions, especially for any medical measures to create a nice quality-of-life. 

This blog is made by: Bella Anastasia Damanik

Class: 2SA05

NPM: 10621381